TOOKAD<sup>®</sup> Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer Review uri icon

Overview

MeSH Major

  • Bacteriochlorophylls
  • Photochemotherapy
  • Photosensitizing Agents
  • Prostatic Neoplasms

abstract

  • Focal VTP treatment with TOOKAD(®) Soluble at 4 mg/kg and 200 J/cm resulted in a negative 6-month biopsy rate of 68.4 % for the whole population and 80.6 % for patients treated by hemiablation with LDI ≥ 1. The treatment was well tolerated. Two phase III studies will reach completion in early 2015.

publication date

  • February 25, 2015

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC4480329

Digital Object Identifier (DOI)

  • 10.1007/s00345-015-1505-8

PubMed ID

  • 25712310

Additional Document Info

start page

  • 945

end page

  • 53

volume

  • 33

number

  • 7